- Advanced search
- Immuno Portal
- Malaria Portal
clindamycin is an approved drug (FDA (1970))
Compound class: Synthetic organic
Comment: Clindamycin is a semisynthetic lincosamide antibiotic with broad-spectrum activity. The compound also has antimalarial activity.
Clindamycin is one of the key access group antibacterials on the World Health Organisation's List of Essential Medicines (link provided in the Classification table below).
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Clindamycin, like a number of other antibiotics including azithromycin and doxycycline, kills the malaria parasite in the lifecycle after treatment starts . Consistent with this slow clinical action, the results provided in the table below show that clindamycin is more potent in vitro against erythrocytic stage parasites when assessed two asexual life cycles after the initiation of treatment.|
|Whole organism assay data|
|Key to terms and symbols||Click on species/strain names for details||Click column headers to sort|